Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Options are complicated and not for the faint of heart. While some investors may use them to take on irresponsible leverage levels on their minor positions, others could use them to express their p...

Hims & Hers stock is down after some political comments by the CEO. However, Q1 earnings remind investors why the business is so good.

Hims reported strong Q1 results that saw revenue surge 46% year over year. The stock fell after some controversial comments from its CEO, but he recently walked them back.

It's been a wild week for HIMS stock — CEO Andrew Dudum said a few things that upset investors. H&H also reported blowout earnings, sending shares higher. People quickly forget that H&H is a brilli...

Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Strong revenue growth continued as the number of users increased 41%. Profits are coming in faster than expected for a company still concerned with growing the top line.

Shares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings results. This quarter is arguably the most important quarter ...

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago.

Shares of Hims & Hers Health Inc. rose after hours on Monday after the online wellness platform bumped its full-year sales forecast higher, following sharp increases in subscribers and profits duri...

Hims & Hers founder and CEO Andrew Dudum said Sunday that his earlier comments praising anti-Israel protesters on college campuses were "misconstrued by some."

Hims & Hers Health stock declined Friday by about 8% after CEO Andrew Dudum's praise for anti-Israel campus protesters in a social media post last week.

Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.

After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings es...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $12.50, signifying a +1.87% move from its prior day's close.